MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$1,629K
Net Income
-$21,831K
Net Profit Margin
-1340.15%
EPS
-$0.15
Unit: Thousand (K) dollars
Revenue Breakdown
License And Service
Laboratory Research Revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
1,629
1,996
1,295
3,299
Cost of revenue
218
395
532
538
Research and development
18,066
15,657
16,584
13,028
General and administrative
6,048
6,743
5,576
4,871
Licensing
1,235
1,393
937
1,911
Revaluation of contingent consideration
300
-
400
100
Total costs and expenses
25,867
24,188
24,029
20,448
Loss from operations
-24,238
-22,192
-22,734
-17,149
Interest income
1,761
1,514
1,634
1,819
Non-cash royalty income
972
854
1,305
716
Total other income
2,733
2,368
2,939
2,535
Net loss
-21,505
-19,824
-19,795
-14,614
Unrealized (loss) gain on marketable securities, net of tax of 0
-326
-588
13
115
Total other comprehensive (loss) income
-326
-588
13
115
Comprehensive loss
-21,831
-20,412
-19,782
-14,499
Basic EPS
-0.15
-0.15
-0.161
-0.12
Diluted EPS
-0.15
-0.15
-0.161
-0.12
Basic Average Shares
142,736,848
128,810,050
122,668,383
122,619,311
Diluted Average Shares
142,736,848
128,810,050
122,668,383
122,619,311
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
ACRS Income Statement Sankey Diagram
Sankey diagram visualizing ACRS income statement for the period
Comprehensive loss
-$21,831K
(-41.93%↓ Y/Y)
Interest income
$1,761K
(-12.74%↓ Y/Y)
Non-cash royalty income
$972K
(1.14%↑ Y/Y)
Net loss
-$21,505K
(-39.38%↓ Y/Y)
Total other
comprehensive (loss) income
-$326K
(-779.17%↓ Y/Y)
Total other income
$2,733K
(-8.26%↓ Y/Y)
License And Service
$1,273K
Laboratory Research
Revenue
$356K
Loss from operations
-$24,238K
(-31.67%↓ Y/Y)
Unrealized (loss) gain on
marketable securities, net...
-$326K
(-779.17%↓ Y/Y)
Total revenue
$1,629K
(-8.33%↓ Y/Y)
Total costs and
expenses
$25,867K
(28.15%↑ Y/Y)
Research and development
$18,066K
(57.80%↑ Y/Y)
General and
administrative
$6,048K
(12.29%↑ Y/Y)
Licensing
$1,235K
(-7.49%↓ Y/Y)
Revaluation of contingent
consideration
$300K
(-80.00%↓ Y/Y)
Cost of revenue
$218K
(-57.67%↓ Y/Y)
Buy us a coffee
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)